In the third quarter of the year, thanks to American plants, the company will deliver 40 million vaccine doses to the European market.
The European Medicines Agency (EMA) has decided to approve an increase in the production of the active substance of the coronavirus vaccine developed by the American company Moderna at factories in the United States. This is stated in the statement of the European pharmaceutical regulator, published on its website on Friday.
“The EMA Committee on Human Medicines has approved the expansion of the production of the active substance of the Moderna coronavirus vaccine in the United States,” the text says. At the same time, it is indicated that this recommendation will significantly impact the supply of the drug to the European Union. “It is assumed that in the third quarter of 2021, thanks to the plants located in the United States, [the company] will supply 40 million doses of the vaccine to the European market,” the pharmaceutical regulator emphasizes.
At the same time, it is clarified that, according to the conclusions of the EMA, two recently approved Moderna enterprises in the United States – plants in Norwood, a suburb of Boston (Massachusetts), and Portsmouth (New Hampshire)-can produce high – quality active substances permanently and will allow Moderna to increase production capacity.
Since the issuance of a conditional permit for the release of the Moderna drug, the EMA Committee on Human Medicines has approved the production of the active substance of this vaccine by a total of four enterprises: two in the United States and two in Switzerland.